Cargando…
Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2
The poly(ADP-ribose) polymerase (PARP) family represents a new class of therapeutic targets with diverse potential disease indications. PARP1 and PARP2 inhibitors have been developed for breast and ovarian tumors manifesting double-stranded DNA-repair defects, whereas tankyrase 1 and 2 (TNKS1 and TN...
Autores principales: | Qiu, Wei, Lam, Robert, Voytyuk, Oleksandr, Romanov, Vladimir, Gordon, Roni, Gebremeskel, Simon, Vodsedalek, Jakub, Thompson, Christine, Beletskaya, Irina, Battaile, Kevin P., Pai, Emil F., Rottapel, Robert, Chirgadze, Nickolay Y. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Union of Crystallography
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188013/ https://www.ncbi.nlm.nih.gov/pubmed/25286857 http://dx.doi.org/10.1107/S1399004714017660 |
Ejemplares similares
-
X-CHIP: an integrated platform for high-throughput protein crystallization and on-the-chip X-ray diffraction data collection
por: Kisselman, Gera, et al.
Publicado: (2011) -
The telomeric PARP, tankyrases, as targets for cancer therapy
por: Seimiya, H
Publicado: (2006) -
Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11)
por: Qiu, Wei, et al.
Publicado: (2014) -
Tankyrase regulates epithelial lumen formation via suppression of Rab11 GEFs
por: Chandrakumar, Arun A., et al.
Publicado: (2021) -
Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1
por: Ryan, Kevin, et al.
Publicado: (2021)